logo
Plus   Neg
Share
Email

AMG Advanced Metallurgical Q1 Profit Declines - Quick Facts

AMG Advanced Metallurgical Group N.V. (AMVMF.PK) posted first quarter net profit attributable to shareholders of $3.5 million or $0.13 per share, lower than $6.97 million or $0.25 per share last year.

Adjusted earnings per share dropped to $0.26 from $0.35 in the same quarter a year ago.

Revenue grew to $323.98 million from $318 million in the prior-year quarter.

Heinz Schimmelbusch, Chairman of the Management Board and CEO, said, "Business was challenging in the first quarter 2012. Demand improved in a number of Advanced Materials products but that was not enough to offset increased costs in mine-based businesses, resulting in a decline in EBITDA. Engineering Systems' order intake was encouraging; however, pricing pressure and changes in product mix resulted in an unsatisfactory performance..."

Moving ahead, despite global uncertainties, AMG targets an increase in revenue and EBITDA in 2012.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT